Methods to precisely diagnose prediabetes and diabetes by identifying associated biomarkers have been proposed to prevent or delay advanced stages of the disease; however, currently known biomarkers like the glycated proteins hemoglobin (HbA1c) and albumin are limited by poor sensitivity of detection and inaccuracy under certain clinical contexts.
Additionally, the American Diabetes Association and the World Health Organization differ in their recommended healthy thresholds for fasting plasma glucose concentrations and HbA1c testing requirements. As such, there is mounting interest in identifying multiple biomarkers during the prediabetic or early diabetic stage to predict and prevent full-blown diabetic onset.
This white paper from SomaLogic describes a need for additional biomarkers to predict the risk of developing type 2 diabetes mellitus and the application of the SomaScan Proteomic Platform to identify serum proteins associated with diabetic risk and outcome.
Offered Free by: SomaLogic
See All Resources from: SomaLogic